Biotech

Med and Bio Tech Patent Box Bill Introduced to Parliament

February 21st, 2022

The Australian Government first announced that it will introduce a patent box for eligible income associated with new patents in the medical and biotechnology sectors in the May 2021 federal budget. The legislation to enact this was introduced to the lower house in February, but with very few Senate sitting days left before the federal election it may not be passed in time. The Tax Concession for Australian Medical Innovations Bill 2022 introduces a patent box scheme that would see […]

Read More

Australian-Based Immutep Ltd Receives $3.63M AUD from French R&D Tax Incentive

June 11th, 2020

Sydney-based company Immutep Ltd has recently announced that it received a €2,173,454 (~A$3,630,000) R&D Tax Incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The payment relates to activity the company is conducting in Paris to develop its novel Immunotherapy treatment. Immutep Ltd also registers activities under the Australian R&D Tax Incentive and has previously reported the following receipts: YE 30 June 2018 – $872,000; YE 30 June 2019 – $1,290,000. Whilst there is […]

Read More

CSL Moves Up International Biotech Market Capitalisation Rankings Driven By R&D Investment

January 20th, 2020

A report in the Australian Financial Review has highlighted the remarkable performance of CSL over recent years, largely due to the company’s investment in R&D Activity. The report has highlighted: CSL’s share price has increased more than 50% during 2019, which is rare for a company of such size and maturity; If CSL maintains their current trajectory, it may shortly overtake Commonwealth Bank of Australia as the 2nd most valuable stock on the ASX by market capitalisation; CSL is now […]

Read More

Cochlear calls for stability to R&D Tax Policy with release of FY19 Results

August 19th, 2019

In comments published in The Australian coinciding with the release of their FY19 financial report, Cochlear has called on the Australian government to adapt policies to ensure Australia remains competitive in attracting global investment in R&D Activity.   CEO Dig Howitt noted specifically that the R&D Tax Incentive must be subject to a stable policy platform to address Australia’s declining R&D Expenditure when quantified as a proportion of GDP.   Dig Howitt had previously mentioned at the AFR Innovation Summit that […]

Read More

Categories

Archives